Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)
October 29, 2024 4:03 PM
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $1,242.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
